AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials
OCALA, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed its At-The-Market (ATM) facility and closed the ATMs Equity Distribution Agreement (EDA).
- OCALA, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed its At-The-Market (ATM) facility and closed the ATMs Equity Distribution Agreement (EDA).
- Management believes, based on the companys current financial condition, that it has adequate funds to meet its anticipated operational cash needs and fund current clinical trials over approximately the next twenty-four months.
- Our team at AIM will work hard to achieve material forward progress to accomplish our clearly stated objectives.
- We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.